Average Ratings 0 Ratings

Total
ease
features
design
support

No User Reviews. Be the first to provide a review:

Write a Review

Average Ratings 0 Ratings

Total
ease
features
design
support

No User Reviews. Be the first to provide a review:

Write a Review

Description

Artrya collaborates with healthcare facilities that treat chest pain patients to introduce innovative cardiovascular care models powered by artificial intelligence. This approach seamlessly incorporates high-prognostic plaque characteristics into the assessment of coronary artery disease. It enables swift evaluations of chest pain patients in both emergency and primary care environments. Our vision is a society free from the burden of heart attacks. Leveraging AI-generated insights from coronary computed tomography angiography (CCTA), we can rapidly and accurately classify chest pain patients based on the type and quantity of arterial plaque identified. This allows for quick identification of individuals with little to no coronary artery disease, ensuring that no underlying plaque issues could lead to significant cardiac events in the future. By recognizing early indicators of potential heart attacks, we can effectively confirm at-risk patients with acute or unusual chest pain who may require additional investigation and treatment. Ultimately, this advancement aims to enhance patient outcomes and foster a healthier community.

Description

Specialty and rare diseases often encompass patient populations that are not clearly defined, including individuals who remain undiagnosed or face misdiagnoses, along with healthcare providers who may lack knowledge about these conditions and their various manifestations, resulting in treatment pathways that are poorly understood. IPM.ai operates as an Insights-as-a-Service (IaaS) firm, dedicated to empowering leading life sciences organizations to gain deeper insights into patient care and enhance the quality of life for those affected through the development, clinical research, and commercialization of therapeutic solutions. By predicting market size, analyzing the competitive landscape, and estimating potential return on investment, companies can optimize their commercialization strategies. Additionally, the platform identifies undiagnosed and misdiagnosed individuals who could benefit from early disease interception and therapeutic measures. It employs statistical models to gauge the prevalence of specific diseases within certain patient populations at any given moment. Furthermore, IPM.ai helps pinpoint physicians who are adept at diagnosing and treating these ideal patients, while also influencing other healthcare providers to enhance overall patient outcomes. This comprehensive approach ultimately aims to bridge the gap in understanding and addressing the needs of those with rare diseases.

API Access

Has API

API Access

Has API

Screenshots View All

Screenshots View All

Integrations

No details available.

Integrations

No details available.

Pricing Details

No price information available.
Free Trial
Free Version

Pricing Details

No price information available.
Free Trial
Free Version

Deployment

Web-Based
On-Premises
iPhone App
iPad App
Android App
Windows
Mac
Linux
Chromebook

Deployment

Web-Based
On-Premises
iPhone App
iPad App
Android App
Windows
Mac
Linux
Chromebook

Customer Support

Business Hours
Live Rep (24/7)
Online Support

Customer Support

Business Hours
Live Rep (24/7)
Online Support

Types of Training

Training Docs
Webinars
Live Training (Online)
In Person

Types of Training

Training Docs
Webinars
Live Training (Online)
In Person

Vendor Details

Company Name

Artrya

Country

Australia

Website

www.artrya.com

Vendor Details

Company Name

IPM.ai

Country

United States

Website

www.ipm.ai/platform

Product Features

Product Features

Alternatives

Alternatives